HK1062806A1 - Novel methods for the treatment and prevention of pain using stress- activated protein kinase inhibitors - Google Patents

Novel methods for the treatment and prevention of pain using stress- activated protein kinase inhibitors

Info

Publication number
HK1062806A1
HK1062806A1 HK04105622.1A HK04105622A HK1062806A1 HK 1062806 A1 HK1062806 A1 HK 1062806A1 HK 04105622 A HK04105622 A HK 04105622A HK 1062806 A1 HK1062806 A1 HK 1062806A1
Authority
HK
Hong Kong
Prior art keywords
pain
prevention
stress
treatment
protein kinase
Prior art date
Application number
HK04105622.1A
Other languages
English (en)
Inventor
Lisa D Aimone
Robert L Hudkins
Mathew S Miller
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of HK1062806A1 publication Critical patent/HK1062806A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HK04105622.1A 2001-05-16 2004-07-29 Novel methods for the treatment and prevention of pain using stress- activated protein kinase inhibitors HK1062806A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29122701P 2001-05-16 2001-05-16
US10/146,680 US7018999B2 (en) 2001-05-16 2002-05-15 Methods for the treatment and prevention of pain
PCT/US2002/015667 WO2002092065A2 (en) 2001-05-16 2002-05-16 Novel methods for the treatment and prevention of pain using stress-activated protein kinase inhibitors

Publications (1)

Publication Number Publication Date
HK1062806A1 true HK1062806A1 (en) 2004-11-26

Family

ID=26844179

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04105622.1A HK1062806A1 (en) 2001-05-16 2004-07-29 Novel methods for the treatment and prevention of pain using stress- activated protein kinase inhibitors

Country Status (13)

Country Link
US (1) US7018999B2 (es)
EP (1) EP1389100B1 (es)
JP (1) JP2004534751A (es)
AR (1) AR035971A1 (es)
AT (1) ATE410201T1 (es)
AU (1) AU2002342715A1 (es)
CA (1) CA2447091C (es)
DE (1) DE60229233D1 (es)
DK (1) DK1389100T3 (es)
ES (1) ES2314101T3 (es)
HK (1) HK1062806A1 (es)
MX (1) MXPA03010451A (es)
WO (1) WO2002092065A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7241779B2 (en) * 2003-12-23 2007-07-10 Cephalon, Inc. Fused pyrrolocarbazoles
US7169802B2 (en) * 2003-12-23 2007-01-30 Cephalon, Inc. Fused pyrrolocarbazoles
AR074374A1 (es) 2008-11-19 2011-01-12 Cephalon Inc Formas de un compuesto de pirrolocarbazol fusionado, composiciones que las comprenden y su uso en el tratamiento de la angiogénesis y los tumores sólidos.

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1381031A (en) 1920-01-19 1921-06-07 Thompson James Dumping-wagon
US4923986A (en) 1987-03-09 1990-05-08 Kyowa Hakko Kogyo Co., Ltd. Derivatives of physiologically active substance K-252
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
JPH07113027B2 (ja) 1987-12-24 1995-12-06 協和醗酵工業株式会社 Ｋ−２５２誘導体
AU3064992A (en) 1991-11-08 1993-06-07 University Of Southern California Compositions containing k-252 compounds for potentiation of neurotrophin activity
US5621101A (en) 1992-07-24 1997-04-15 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US5756494A (en) 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
ATE165097T1 (de) 1993-05-28 1998-05-15 Cephalon Inc Anwendung von indolocarbazol-derivaten zur behandlung von prostataerkrankungen
US5534426A (en) 1993-07-19 1996-07-09 The Regents Of The University Of California Oncoprotein protein kinase
US6514745B1 (en) 1993-07-19 2003-02-04 The Regents Of The University Of California Oncoprotein protein kinase
US5468872A (en) 1993-09-16 1995-11-21 Cephalon, Inc. K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders
WO1995022331A1 (en) 1994-02-18 1995-08-24 Cephalon, Inc. Aqueous indolocarbazole solutions
US5594009A (en) 1994-10-14 1997-01-14 Cephalon, Inc. Fused pyrrolocarbazoles
US5705511A (en) 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
US6046208A (en) 1996-01-11 2000-04-04 Smithkline Beecham Corporation Substituted imidazole compounds
US5616724A (en) 1996-02-21 1997-04-01 Cephalon, Inc. Fused pyrrolo[2,3-c]carbazole-6-ones
UA67725C2 (en) 1996-06-03 2004-07-15 Cephalon Inc K-252a derivatives and a method for improvement of functioning and cell survival enhancement
BR9710693A (pt) 1996-06-25 2000-01-11 Cephalon Inc Uso de um derivado de k-252a para o tratamento do nervo central ou periférico e super produção de citoquinona.
CN1285836A (zh) 1997-12-31 2001-02-28 赛福伦公司 3′－差向异构的K－252a衍生物
ATE212552T1 (de) 1998-04-17 2002-02-15 Tufts College Map kinase-inhibitoren zur behandlung von durch tnf-alpha induzierte lipolyse- verursachte krankheiten
US6811992B1 (en) 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions
GB9811624D0 (en) 1998-05-29 1998-07-29 Merck Sharp & Dohme Therapeutic use
US6127401A (en) 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
US6207687B1 (en) 1998-07-31 2001-03-27 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
CZ2001701A3 (cs) 1998-08-26 2002-04-17 Cephalon, Inc. Způsob identifikace sloučeniny, která pozměňuje aktivitu kinasových proteinů s násobnou vazbou
JP2002532503A (ja) 1998-12-17 2002-10-02 エフ．ホフマン−ラ ロシュ アーゲー プロテインキナーゼ阻害剤としての４，５−ピラジノオキシンドール
AU771599B2 (en) 1998-12-17 2004-03-25 F. Hoffmann-La Roche Ag 4- and 5-alkynyloxindoles and 4- and 5-alkenyloxindoles
EP1149093A1 (en) 1998-12-17 2001-10-31 F. Hoffmann-La Roche Ag 4-aryloxindoles as inhibitors of jnk protein kinases
US6841567B1 (en) 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones
AU4483000A (en) 1999-04-23 2000-11-10 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk)
AU5316900A (en) 1999-06-03 2000-12-28 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk)
ES2260033T3 (es) 1999-07-02 2006-11-01 Stuart A. Lipton Uso de los inhibidores p38 mapk en efermadades oftalmicas.
HUP0202319A3 (en) 1999-07-16 2004-12-28 Warner Lambert Co Use of mek inhibitors for the preparation of pharmaceutical compositions treating chronic pain
SK3572002A3 (en) 1999-08-13 2002-07-02 Vertex Pharma Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
NZ517578A (en) 1999-08-19 2004-02-27 Signal Pharm Inc Pyrazoloanthrone and derivatives thereof as JNK inhibitors and their compositions
US6399780B1 (en) 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
WO2001091749A1 (en) 2000-06-01 2001-12-06 Merck & Co., Inc. Use of (di-substituted-phenyl)-pyrimidinyl-imidazole derivatives as jnk-inhibitors
AU2002228911A1 (en) 2000-11-08 2002-05-21 The General Hospital Corporation Methods for inhibiting pain
CA2430539C (en) 2000-12-05 2010-07-13 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases

Also Published As

Publication number Publication date
ES2314101T3 (es) 2009-03-16
US20030087899A1 (en) 2003-05-08
CA2447091C (en) 2012-03-27
EP1389100A2 (en) 2004-02-18
CA2447091A1 (en) 2002-11-21
DK1389100T3 (da) 2008-12-08
ATE410201T1 (de) 2008-10-15
DE60229233D1 (de) 2008-11-20
MXPA03010451A (es) 2004-05-05
AR035971A1 (es) 2004-07-28
WO2002092065A3 (en) 2003-07-31
WO2002092065A2 (en) 2002-11-21
US7018999B2 (en) 2006-03-28
EP1389100B1 (en) 2008-10-08
JP2004534751A (ja) 2004-11-18
AU2002342715A1 (en) 2002-11-25

Similar Documents

Publication Publication Date Title
HK1079426A1 (en) Use of ikappab kinase inhibitors for the treatment of pain
GB2393202B (en) Methods of well treatment
AU2002351397A8 (en) Systems and methods using vasoconstriction for improved thermal treatment of tissues
AU2002310187A1 (en) Inhibitors of protein kinase for the treatment of disease
HK1068874A1 (en) Heterocyclic compounds and methods of use
HRP20041029A2 (en) Therapeutic use of selcetive pde10 inhibitors
PL364111A1 (en) Methods of treating inflammatory and immune diseases using inhibitors of ikappab kinase (ikk)
GB0213869D0 (en) The treatment of pain
EP1359885A4 (en) NOS-HEMMER FOR THE TREATMENT OF WRINKLES
AU2003210983A8 (en) Kinase inhibitors and methods of use thereof
HUP0303306A3 (en) Use of il-18 inhibitors for the treatment and/or prevention of heart disease
GB0211295D0 (en) Treatment of pain
GB0124124D0 (en) Methods of treatment
EP1389105A4 (en) METHOD OF TREATMENT
GB0112216D0 (en) Method of treatment
HK1062806A1 (en) Novel methods for the treatment and prevention of pain using stress- activated protein kinase inhibitors
GB0118892D0 (en) Method of treatment
GB2410744B (en) Kinase inhibitors for the treatment of disease
IL161630A0 (en) Methods of treating endometreosis
GB0221712D0 (en) Methods of treatment
GB0100092D0 (en) Treatment of degenerative diseases
EP1303281A4 (en) METHODS OF TREATMENT
AU2003294697A8 (en) Combinations of benzodithiazoles and cox-2 inhibitors for the treatment of pain
GB0222505D0 (en) Treatment of pain
GB0216978D0 (en) The treatment of pain

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20140516